A role for the Val291 residue within the transmembrane domain 2 in diltiazem- And TMB-8 [3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester]-mediated 5-hydroxytryptamine type 3A receptor regulations

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 5, 2009, Pages 861-867

  Lee, Byung Hwan ^a   Choi, Sun Hye ^a   Pyo, Mi Kyung ^a   Shin, Tae Joon ^a   Hwang, Sung Hee ^a   Kim, Bo Ra ^a   Lee, Jun Ho ^b   Rhim, Hyewhon ^c   Kim, Hyoung Choon ^d   Nah, Seung Yeol ^a  

^a Konkuk University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d Kangwon National University   (South Korea)

Author keywords

3,4,5 trimethoxybenzoic acid 8 (diethylamino)octyl ester; 5 hydroxytryptamine type 3A receptor; common interaction site; Diltiazem

Indexed keywords

3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; AMINO ACID; DILTIAZEM; SEROTONIN 3A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG STRUCTURE; GENE EXPRESSION SYSTEM; IC 50; ION CURRENT; MUTATIONAL ANALYSIS; NONHUMAN; OOCYTE; PROTEIN DOMAIN; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; VOLTAGE CLAMP; XENOPUS LAEVIS;

AMINO ACID SEQUENCE; ANIMALS; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GALLIC ACID; ION CHANNEL GATING; MEMBRANE POTENTIALS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, SEROTONIN, 5-HT3; VALINE; XENOPUS LAEVIS;

EID: 66749110409     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.861     Document Type: Article

References (23)

1. Keramidas A., Moorhouse A. J., Schofield P. R., Barry P. H., Prog. Biophys. Mol. Biol., 86, 161-204 (2004).
2. Lummis S. C., Biochem. Soc. Trans., 32, 535-539 (2004).
3. Zhang L., Hosoi M., Fukuzawa M., Sun H., Rawlings R. R., Weight F. F., J Biol. Chem., 277, 46256-46264 (2002).
4. Hu X. Q., Zhang L., Stewart R. R., Weight F. F., J. Biol. Chem., 278, 46583-16589 (2003).
5. Reeves D. C., Goren E. N., Akabas M. H., Lummis S. C., J Biol. Chem., 276, 42035-42042 (2001).
6. Panicker S., Cruz H., Arrabit C., Slesinger P. A., J. Neurosci., 22, 1629-1639 (2002).
7. Panicker S., Cruz H., Arrabit C., Suen K. F., Slesinger P. A., J. Biol. Chem., 279, 28149-28158 (2004).
8. Dang H., England P. M., Farivar S. S., Dougherty D. A., Lester H. A., Mol. Pharmacol., 57, 1114-1122 (2000).
9. Lopreato G. F., Banerjee P., Mihic S. J., Mol. Brain Res., 118, 45-51 (2003).
10. Spedding M., Paoletti R., Pharmacol. Rev., 44, 363-376 (1992).
11. Bencherif M., Eisenhour C. M., Prince R. J., Lippiello P. M., Lukas R. J., J. Pharmacol. Exp. Ther., 275, 1418-1426 (1995).
12. Houlihan L. M., Slater E. Y., Beadle D. J., Lukas R. J., Bermudez I., Neuropharmacology, 39, 2533-2542 (2000).
13. Hargreaves A. C., Gunthorpe M. J., Taylor C. W., Lummis S. C., Mol. Pharmacol., 50, 1284-1294 (1996).
14. Sun H., McCardy E. A., Machu T. K., Blanton M. P., J. Pharmacol. Exp. Ther., 290, 129-135 (1999).
15. Gunthorpe M. J., Lummis S. C., J. Physiol., 519, 713-722 (1999).
16. Dascal N., CRC Crit. Rev. Biochem., 22, 317-387 (1987).
17. Choi S., Lee J. H., Oh S., Rhim H., Lee S. M., Nah S. Y., Mol. Cells, 15, 108-113 (2003).
18. Lee B. H., Jeong S. M., Lee J. H., Kim J. H., Kim D. H., Park C. S., Lee S. M., Nah S. Y., Mol. Cells, 18, 115-121 (2004).
19. Maricq A. V, Peterson A. S., Brake A. J., Meyers R. M., Julius D., Science, 254, 432-437 (1991).
20. White M. M., Aylwin M., Mol. Pharmacol., 37, 720-724 (1990).
21. Lee B. H., Lee Jun Ho, Lee S. M., Jeong S. M., Yoon I. S., Lee Joon Hee, Choi S. H., Pyo M. K., Rhim H., Kim H. C., Jang C. G., Lee B. C., Park C. S., Nah S. Y., Neuropharmacology, 52, 1139-1150 (2007).
22. Bertrand D., Devillers-Thiery, A., Revah F., Galzi J. L., Hussy N., Mulle C., Bertrand S., Ballivet M., Changeux J. P., Proc. Natl. Acad. Sci. U.S.A., 89, 1261-1265 (1992).
23. Buisson B., Bertrand D., Mol. Pharmacol., 53, 555-563 (1998).